Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

20043,681 citationsJournal Articlebronze Open Access

Authors

Daniel P. Petrylak · Columbia University Irving Medical Center

Catherine M. Tangen · Cancer Research And Biostatistics

Maha Hussain · University of Michigan–Ann Arbor

Primo N. Lara

Jeffrey A. Jones · Baylor College of Medicine

Mary Ellen Taplin · University of Massachusetts Chan Medical School

Patrick A. Burch · Mayo Clinic in Arizona

Abstract

The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.

Topics & Keywords

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Multiple Myeloma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 351, Issue 15, pp. 1513-1520

DOI: 10.1056/nejmoa041318

Field-Weighted Citation Impact: 152.83